EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years

Terhi K Friman iD, Birgitta Salmela, Ilkka Helanterä, Fredrik Åberg, Timo Jahnukainen, Maija Halme, Samuli Vaittinen, Jyri Lommi, Markku O Pentikäinen, Panu E Kovanen, Sirpa Leppä, Riikka Räty

Hematological Oncology · 2026

DOI: 10.1002/hon.70177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Terhi K Friman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Lymphoproliferative Disorders, Organ Transplantation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helsinki University Hospital, Scandiatransplant, Finnish Foundation for Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients ( n = 6555), both adults and children, over a 30‐year period in Finland. Altogether, 215 patients developed PTLD, including 146 aggressive B‐cell lymphomas, in a median of 7.8 years after SOT. The incidence of PTLD was 322 per 100,000 patient‐years. In median follow‐up of 11.5 years after PTLD diagnoses, 155 patients deceased, 119 (55%) of them PTLD related. The median overall survival (OS) was 1.7 years for all. After curatively intended therapy ( n = 165), the median OS was 6.1 years, 5‐year OS rate 52%, and 5‐year disease‐specific survival (DSS) 58%. In all, 120 patients (56%) achieved complete remission (CR); 69% receiving first‐line rituximab and 73% with chemotherapy, and their 5‐year DSS rate was 79%. Relapses or second PTLD was recorded in 55 patients (36%) in a median of 1.5 years, and ten cases occurred over five years after the original PTLD diagnosis. International Prognostic Index (IPI) and age over 45 years at PTLD diagnosis were associated with inferior outcomes. Early deaths (< 100 days; n = 60; 28%) were related to progressive PTLD or treatment‐related complications. However, a decreasing trend in 100‐day mortality was observed, with improved DSS over the study period (1988–2002 compared with 2003–2017, p = 0.011), despite increased median age at PTLD diagnosis. In conclusion, early mortality remained high throughout the study period. In a long follow‐up, the relapses were a major problem even after 5 years. PTLD related mortality rate was remarkably lower in more recent years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoproliferative DisordersOrgan TransplantationHumansFemaleFinlandMaleMiddle AgedAdultPrognosisAdolescentChildAgedChild, PreschoolYoung AdultSurvival RateFollow-Up StudiesInfant

Stichwörter der Autor:innen

disease recurrencelymphoproliferative disordersorgan transplantationprognosissurvival rate

Autor:innen und Institutionen

  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Department of Internal Medicine, Heart Center, Päijät-Häme Central Hospital, Lahti, Finland.
  • Department of Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Pediatric Nephrology and Transplantation, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Pulmonology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland.

ORCID-Profile: Terhi K Friman

Förderung

  • Helsinki University Hospital
  • Scandiatransplant
  • Finnish Foundation for Cardiovascular Research

Zitieren

APA

Friman, T. K., Salmela, B., Helanterä, I., Åberg, F., Jahnukainen, T., Halme, M., Vaittinen, S., Lommi, J., Pentikäinen, M. O., Kovanen, P. E., Leppä, S., & Räty, R. (2026). Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years. Hematological Oncology. https://doi.org/10.1002/hon.70177

Vancouver

Friman TK, Salmela B, Helanterä I, Åberg F, Jahnukainen T, Halme M, et al. Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years. Hematological Oncology. 2026. doi:10.1002/hon.70177

BibTeX
@article{Friman2026,
  author = {Friman, Terhi K and Salmela, Birgitta and Helanterä, Ilkka and Åberg, Fredrik and Jahnukainen, Timo and Halme, Maija and Vaittinen, Samuli and Lommi, Jyri and Pentikäinen, Markku O and Kovanen, Panu E and Leppä, Sirpa and Räty, Riikka},
  title = {Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70177}
}
Kostenlos starten →